New adamantane-based spiro 1,2,4-trioxanes orally effective against rodent and simian malaria

Journal of Medicinal Chemistry

Volumn 50, Issue 3, 2007, Pages 521-527

  Singh, Chandan ^a   Kanchan, Rani ^a   Sharma, Upasana ^a   Puri, Sunil K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIOXANE DERIVATIVE; 3 (1 ADAMANTAN 1 YL VINYL) 1,2,5 TRIOXASPIRO[5.5]UNDECANE; 8 (1 ADAMANTAN 1 YL VINYL) 6,7,10 TRIOXASPIRO[4.5]DECANE; ADAMANTANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; MALARIA; MOUSE; NONHUMAN; PLASMODIUM YOELII; RHESUS MONKEY;

ADAMANTANE; ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; DRUG RESISTANCE; HETEROCYCLIC COMPOUNDS, 1-RING; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MALARIA; MICE; PARASITEMIA; PLASMODIUM CYNOMOLGI; PLASMODIUM YOELII; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846926709     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0610043     Document Type: Article

References (49)

1. Central Drug Research Institute (CDRI) communication number: 6920.
2. WHO: Drug Information Bulletin 1999, 13, 9.
3. For reviews on artemisinin and its analogues, see: (a) Klayman, D. L. Qinghaosu (artemisinin): An antimalarial drug from China. Science 1985, 228, 1049-1055.
4. (b) Luo, X. D.; Shen, C. C. The chemistry, pharmacology, and clinical applications of qinghaosu (artemisinin) and its derivatives. Med. Res. Rev. 1987, 7, 29-52.
5. (c) Cumming, J. N.; Ploypradith, P.; Posner, G. H. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes. Adv. Pharmacol. 1997, 37, 253-297.
6. (d) Bhattacharya, A. K.; Sharma, R. P. Recent developments on the chemistry and biological activity of artemisinin and related antimalarials. Heterocycles 1999, 51, 1681-1745.
7. (e) Borstnik, K.; Paik, I.; Shapiro, T. A.; Posner, G. H. Antimalarial chemotherapeutic peroxides: Artemisinin, yingzhaosu A, and related compounds. Int. J. Parasitol. 2002, 32, 1661-1667.
8. (f) Ploypradith, P. Development of artemisinin and its structurally simplified trioxane derivatives as antimalarial drugs. Acta Trop. 2004, 89, 329-342.
9. (g) O'Neill, P. M.; Posner, G. H. A Medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. 2004, 47, 2945-2964.
10. (a) Asthana, O. P.; Srivastava. J. S.; Valecha, N. Current status of the artemisinin derivatives in the treatment of malaria with focus on arteelher. J. Parasit. Dis. 1997, 211, 1-12.
11. (b) WHO: Facts on ACTs (Artemisinin-based Combination Therapies), http://www.rbm.who.int/cmc.
12. (a) Kepler, J. A.; Philip, A.; Lee, Y. W.; Matthew, C.; Morey, M. C.; Carroll, F. I. 1,2,4-Trioxanes as potential antimalarial agents. J. Med. Chem. 1988, 31, 713-716.
13. (b) Peters, W.; Robinson, B. L.; Tovey, G.; Rossier, J. C.; Jefford, C. W. The chemotherapy of rodent malaria. XLVIIl. The activities of some synthetic 1,2,4-trioxanes against chloroquine-sensitive and chloroquine-resistant parasites. Part 1: Studies leading to the development of novel cis-fused cyclopenteno derivatives. Ann. Trop. Med. Parasitol. 1993, 87, 1-7.
14. (c) Peters, W.; Robinson, B. L.; Rossier, J. C.; Jefford, C. W. The chemotherapy of rodent malaria. XLIX. The activities of some synthetic 1,2,4-trioxanes against chloroquine-sensitive and chloroquine-resistant parasites. Part 2: Structure-activity studies on cis-fused cyclopenteno1,2,4- trioxanes (fenozans) against drug-sensitive and drug-resistant lines of Plasmodium berghei and P. yoelii ssp. NS in vivo. Ann. Trop. Med. Parasitol. 1993, 87, 9-16.
15. (d) Peters, W.; Robinson, B. L.; Tovey, G.; Rossier, J. C.; Jefford, C. W. The chemotherapy of rodent malaria. L. The activities of some synthetic 1,2,4-trioxanes against chloroquine-sensitive and chloroquine-resistant parasites. Part 3: Observations on 'Fenozan-50F', a difluorinated 3,3′-spirocyclopentane 1,2,4-trioxane. Ann. Trop. Med. Parasitol. 1993, 87, 111-123.
16. (e) Posner, G. H.; Maxwell, J. P.; O'Dowd, H.; Krasavin, M.; Xie, S.; Shapiro, T. A. Antimalarial sulfide, sulfone, and sulfonamide trioxanes. Bioorg. Med. Chem. 2000, 8, 1361-1370.
17. (f) Posner, G. H.; Jeon, H. B.; Parker, M. H.; Krasavin, M.; Paik, I.-H.; Shapiro, T. A. Antimalarial simplified 3-aryltrioxanes: Synthesis and preclinical efficacy/toxicity testing in rodents. J. Med. Chem. 2001, 44, 3054-3058.
18. (g) Posner, G. H.; Jeon, H. B.; Polypradith, P.; Paik, I.-H.; Borstnik, K.; Xie, S.; Shapiro, T. A. Orally active, water-soluble antimalarial 3-aryltrioxanes: Short synthesis and preclinical efficacy testing in rodents. J. Med. Chem. 2002, 45, 3824-3828.
19. (h) Griesbeck, A. G.; El-Idreesy, T. T.; Fiege, M.; Brun, R. Synthesis of antimalarial 1,2,4-trioxanes via photooxygenation of a chiral allylic alcohol. Org. Lett. 2002, 24, 4193-4195.
20. (i) O'Neill, P. M.; Mukhtar, A.; Ward, S. A.; Bickley, J. F.; Davies, J.; Bachi, M. D.; Stocks, P. A. Application of thiol-olefin co-oxygenation methodology to a new synthesis of the 1,2,4-trioxane pharmacopoeia. Org. Lett. 2004, 18, 3035-3038.
21. (a) Singh, C. Preparation of β-hydroxyhydroperoxides by photooxygenation of allylic alcohols and their elaboration into 1,2,4-trioxanes. Tetrahedron Lett. 1990, 31, 6901-6902.
22. (b) Singh, C.; Gupta, N.; Puri, S. K. Photooxygenation of 3-aryl-2-cyclohexenols: Synthesis of a new series of antimalarial 1,2,4-trioxanes. Tetrahedron Lett. 2005, 46, 205-207.
23. (a) Singh, C.; Misra, D.; Saxena, G.; Chandra, S. Synthesis of in vivo potent antimalarial 1,2,4-trioxanes. Bioorg. Med. Chem. Lett. 1992, 2, 497-500.
24. (b) Singh, C.; Misra, D.; Saxena, G.; Chandra, S. In vivo potent antimalarial 1,2,4-trioxanes: Synthesis and activity of 8-(α-arylvinyl)-6, 7,10-trioxaspiro[4,5]decanes and 3-(α-arylvinyl)-1,2,5-trioxaspiro[5,5] undecanes against Plasmodium berghei in mice. Bioorg. Med. Chem. Lett. 1995, 5, 1913-1916.
25. (c) Singh, C.; Gupta, N.; Puri, S. K. Geraniol-derived 1,2,4-trioxanes with potent in vivo antimalarial activity. Bioorg. Med. Chem. Lett. 2003, 13, 3447-3450.
26. (d) Singh, C.; Malik, H.; Puri, S. K. Synthesis and antimalarial activity of a new series of trioxaquines. Bioorg. Med. Chem. 2004, 12, 1177-1182.
27. (e) Singh, C.; Gupta, N.; Puri, S. K. Synthesis of new 6-alkylvinyl/arylalkylvinyl substituted 1,2,4-trioxanes active against multi-drug resistant malaria in mice. Bioorg. Med. Chem. 2004, 12, 5553-5562.
28. (f) Singh, C.; Srivastav, N. C.; Puri, S. K. Synthesis and antimalarial activity of 6-cycloalkylvinyl substituted 1,2,4-trioxane. Bioorg. Med. Chem. 2004, 12, 5745-5752.
29. (g) Singh, C.; Malik, H.; Puri, S. K. Orally active amino fictionalized antimalarial 1,2,4-trioxanes. Bioorg. Med. Chem. Lett. 2004, 14, 459-462.
30. (h) Singh, C.; Malik, H.; Puri, S. K. New orally active spiro 1,2,4-trioxanes with high antimalarial potency. Bioorg. Med. Chem. Lett. 2005, 15, 4484-4487.
31. (i) Singh, C.; Kanchan, R.; Srivastava, D.; Puri, S. K. 8-(1-Naphthalen-2-yl-vinyl)-6,7,10-trioxaspiro(4.5)decane, a new 1,2,4-trioxane effective against rodent and simian malaria, Bioorg. Med. Chem. Lett. 2006, 16, 584-586.
32. (j) Singh, C.; Malik, H.; Puri, S. K. Orally active 1,2,4-trioxanes: Synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant Plasmodium yoelii nigeriensis in mice. J. Med. Chem. 2006, 49, 2794-2803.
33. (a) Vennerstrom, J. L., Arbe-Barens, S.; Brun, R.; Charman, S. A.; Chiu, F. C. K.; Chollet, J.; Dong, Y.; Dorn, A.; Hunziker, D.; Matile, H.; McIntosh, K.; Padmanilayam, M.; Tomas, J. S.; Scheurer, C.; Scorneaux, B.; Tang, Y.; Urwyler, H.; Urwyler, H.; Wittlin, S.; Charman, W. N. Identification of an antimalarial synthetic trioxaolane drug development candidate. Nature 2004, 430, 900.
34. (b) Dong, Y.; Chollet, J.; Matile, H.; Charman, S. A.; Chiu, F. C. K.; Charman, W. N.; Scorneaux, B.; Urwyler, H.; Tomas, J. S.; Scheurer, C.; Snyder, C.; Dorn, A.; Wang, X.; Karle, J. M..; Tang, Y.; Urwyler, H.; Burn, R.; Vennerstrom, J. L. Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: Charting a workable structure-activity relationship using simple prototypes. J. Med. Chem. 2005, 48, 4953-4961.
35. Greisbeck, A. G.; El-ldreesy, T. T.; Höinck, L.-O.; Lex, J.; Brun, R. Novel spiroanellated 1,2,4-trioxanes with high in vitro antimalarial activities. Bioorg. Med. Chem. Lett. 2005, 15, 595-597.
36. 2-Hydroperoxy-3-(5,6,7,8-tetrahydro-naphthalen-2-yl)-but-3-en-1-ol 9c and 3-adamantan-1-yl-2-hydroperoxy-but-3-en- 1-ol 9g were not isolated and used in situ for preparation of trioxanes 13c, 13g, and 14a,b.
37. (a) Peters, W. Techniques for the study of drug response in experimental malaria. In Chemotherapy and drug resistance in malaria; Academic Press: London. 1970; pp 64-136.
38. 14 The treated mice surviving beyond day 28 were recorded as the mice protected by the drug. Mice treated with β-Arteether served as positive controls.
39. (a) 100% suppression of parasiteamia means that the number of parasites, if at all present, are below the detection limit. The parasites present below the detection limit can multiply and eventually can be detected. In such cases though the drug is providing near 100% suppression of the parasiteamia but will not provide full protection to the treated mice. Multidrug resistant Plasmodium yoelii nigeriensis used in this study is resistant to chloroquine. mefloquine and halofantrine.
40. (b) 100% protection means all the treated mice survive till day 28. Similarly, 50% and 20% protection means only 50% and 20% of the treated mice survive to day 28.
41. 5 parasitized RBC, and treatment was initiated when the parasiteamia level reached above 0.5%. Trioxane 13f was dissolved in groundnut oil and administered 10 mg/kg x 4 days by oral/intramuscular routes and 20 mg/kg x 4 days by oral route. The blood smears from the treated monkeys were examined once daily to record parasiteamia clearance time and subsequent recurrence of parasiteamia.
42. Puri, S. K.; Singh, N. Azithromycin: Antimalarial profile against blood and sporozoite-induced infections in mice and monkeys. Exp. Parasitol. 2000, 94, 8-14.
43. Singh, C.; Chaudhary, S.; Puri, S. K. New orally active derivatives of artemisinin with high efficacy against multi-drug resistant malaria in mice. J. Med. Chem. 2006, 49, 7227-7233.
44. (a) Craig, P. N. Drug Compendium. In Comprehensive Medicinal Chemistry, 1st ed.; Mansch, C., Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press: Oxford, U.K., 1990; Vol. 6, pp 237-965.
45. (b) Cincinelli, R.; Dallavalle, S.; Merlini, L.; Penco, S.; Pisano, C.; Carminati, P.; Giannini, G.; Vesci, L.; Gaetano, C.; Illy, B.; Zuco, V.; Supino, R.; Zunino, F. A novel atypical retinoid endowed with proapoptotic and antitumor activity. J. Med. Chem. 2003, 46, 909-912.
46. (c) Lu, D.; Meng, Z.; Thakur, G. A.; Fan, P.; Steed, J.; Tartal, C. L.; Hurst, D. P.; Reggio, P. H.; Deschamps, J. R.; Parrish, D. A.; George, C.; Jarbe, T. U. C.; Lamb, R. J.; Makriyannis, A. Adamantyl cannabinoids: A novel class of cannabinergic ligands. J. Med. Chem. 2005, 48, 4576-4585.
47. (d) Augeri, D. J.; Robl, J. A.; Betebenner, D. A.; Magnin, D. R.; Khanna, A.; Robertson, J. G.; Wang, A.; Simpkins, L. M.; Taunk, P.; Huang, Q.; Han, S. P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G. E.; Egan, D. M.; Marcinkeviciene, J.; Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R. A.; Hamann, L. G. Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48, 5025-5037.
48. Frenkel, Y. V.; Clark, A. D., Jr.; Das, K.; Wang, Y. H.; Lewi, P. J.; Janssen, P. A. J.; Arnold, E. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J. Med. Chem. 2005, 48, 1974-1983.
49. Belpaire, F. M.; Bogaert, M. G. The Fate of Xenobiotics in Living Organisms. In The Practice of Medicinal Chemistry, 2nd ed.; Wermuth, C. G., Ed.; Academic Press: New York, 2003; pp 501-515.